NCT02175303

A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Karolinska Institutet · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To evaluate safety and efficacy using decidual stromal cell therapy for toxicity and inflammation, with special focus on allogeneic hematopoietic cell transplantation patients. The hypothesis to be tested is that the cells are safe to infuse and that they have an anti-inflammatory and healing effect.

Detailed description

Patients with toxicity, inflammation or hemorrhages will receive decidual stromal cells at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.

Conditions

• Acute Lung Injury
• Decidual Stromal Cells
• Stem Cell Transplantation
• Inflammation

Interventions

Type	Name	Description
BIOLOGICAL	Decidual stromal cell therapy	Decidual stromal cells from placenta will be infused intravenously at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals.

Timeline

• Start date: 2013-12-01
• Primary completion: 2017-12-01
• Completion: 2017-12-01
• First posted: 2014-06-26
• Last updated: 2014-06-26

Locations

1 site across 1 country: Sweden